Precision diagnostics platform provider NGeneBio announced that it has inked a memorandum of understanding(MOU) with Turkish firm Genoks Health Service for the NGS test collaboration.

Through the partnership, NGeneBio will supply its cancer precision diagnostics NGS panels, data analysis software, and nucleic acid extraction systems to Genoks. Genoks, having an R&D laboratory and carrying out more than 80,000 NGS tests, will conduct NGS tests with NGeneBio’s products for samples collected from Turkey, Iran, Azerbaijan, and Cyprus. NGeneBio expects it can expand its market presence to both Middle East and Western Asia through the partnership.

Genoks is a Turkey-based company leading NGS test service market and started to routinely use the NIPT test based on NGS technology for the first time in Turkey.

NGeneBio is a South Korea-based company that was founded in 2015 and has launched clinical NGS kits and analysis/interpretation software covering cancer diagnostics area: BRCA 1&2 (firstly approved by Ministry of Food and Drug Safety in South Korea, and CE-IVD marked), solid tumor (CE-IVD), hematological malignancies (CE-IVD), comprehensive oncology (CE-IVD), HLA-Typing (CE-IVD), and Tuberculosis detection (CE-IVD) products.